Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
| Autor: | Dennis C. Mays, Amy L. Weaver, Richard M. Weinshilboum, Carol L. Szumlanski, Philip W. Lowry, James J. Lipsky, William J. Sandborn, Edward V. Loftus, William J. Tremaine, Curtis L. Franklin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2001 |
| Předmět: |
Adult
Male medicine.medical_specialty Azathioprine Gastroenterology Article chemistry.chemical_compound Mesalazine Pharmacokinetics Sulfasalazine Internal medicine medicine Confidence Intervals Humans Drug Interactions Antipyretic Mesalamine Thioguanine Chromatography High Pressure Liquid Analysis of Variance business.industry Mercaptopurine Anti-Inflammatory Agents Non-Steroidal Leukopenia Methyltransferases Drug interaction Balsalazide Phenylhydrazines Aminosalicylic Acids Binomial Distribution chemistry Immunology Female business Immunosuppressive Agents medicine.drug |
| Popis: | AIM—We evaluated the effect of coadministration of sulphasalazine, mesalamine, and balsalazide on the pharmacokinetics and pharmacodynamics of azathioprine and 6-mercaptopurine. METHODS—Thirty four patients with Crohn's disease receiving azathioprine or 6-mercaptopurine were enrolled in an eight week non-randomised parallel group drug interaction study and treated with mesalamine 4 g/day, sulphasalazine 4 g/day, or balsalazide 6.75 g/day. The primary outcome measure was the occurrence of clinically important leucopenia during the study, defined separately as total leucocyte counts |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|